MedWatch

Novartis and Gilead to launch CAR-T cell therapies in Denmark next year

Global drug group Novartis hopes to treat the first Danish cancer patient with the company's CAR-T cell therapy already by new years, while Gilead aims to be ready "during 2019". However, both companies must first get past the Danish Medicines Council.

Novartis' CAR-T-cell therapy | Foto: Novartis

Only two companies in the world have received permission to market the cancericide CAR-T cell therapies, and both are planning to bring their therapies to Denmark next year.

This is according to Novartis and Gilead, the drug groups behind the CAR-T cell therapies Kymriah and Yescarta.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier